Drug Profile
Diphtheria tetanus pertussis-hepatitis B vaccine - CJ Corporation
Latest Information Update: 29 Aug 2007
Price :
$50
*
At a glance
- Originator CJ Corporation
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diphtheria; Hepatitis B; Pertussis; Tetanus
Most Recent Events
- 29 Aug 2007 Discontinued - Preclinical for Diphtheria in South Korea (IM)
- 29 Aug 2007 Discontinued - Preclinical for Hepatitis B in South Korea (IM)
- 29 Aug 2007 Discontinued - Preclinical for Pertussis in South Korea (IM)